Hudson Bay Capital Management LP Ionis Pharmaceuticals Inc Transaction History

Hudson Bay Capital Management LP

$25.7 Billion
Q2 2025

A detailed history of Hudson Bay Capital Management LP transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 750,000 shares of IONS stock, worth $30.9 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

750,000

Previous 1,049,900 28.56%

Holding current value

$30.9 Million

Previous $31.7 Million 6.45%

% of portfolio

0.12%

Previous 0.11%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$25.51 - $40.0 $7.65 Million - $12 Million	-299,900 Reduced 28.56%	750,000 $29.6 Million
Q1 2025 May 14, 2025	BUY	$30.17 - $34.97 $6.9 Million - $8 Million	228,700 Added 27.85%	1,049,900 $31.7 Million
Q4 2024 Feb 14, 2025	BUY	$33.73 - $40.36 $1.83 Million - $2.19 Million	54,300 Added 7.08%	821,200 $28.7 Million
Q3 2024 Nov 13, 2024	BUY	$40.06 - $51.86 $16.1 Million - $20.8 Million	400,900 Added 109.54%	766,900 $30.7 Million
Q2 2024 Aug 14, 2024	BUY	$36.45 - $47.7 $1.11 Million - $1.45 Million	30,500 Added 9.09%	366,000 $17.4 Million
Q1 2024 May 15, 2024	BUY	$42.03 - $53.55 $8.01 Million - $10.2 Million	190,500 Added 131.38%	335,500 $14.5 Million
Q4 2023 Feb 14, 2024	SELL	$43.39 - $51.63 $1.95 Million - $2.32 Million	-45,000 Reduced 23.68%	145,000 $7.34 Million
Q3 2023 Nov 14, 2023	SELL	$38.5 - $47.13 $3.27 Million - $4.01 Million	-85,000 Reduced 30.91%	190,000 $8.62 Million
Q2 2023 Aug 14, 2023	SELL	$34.73 - $43.33 $1.07 Million - $1.33 Million	-30,800 Reduced 10.07%	275,000 $11.3 Million
Q1 2023 May 15, 2023	BUY	$33.58 - $41.2 $2.71 Million - $3.33 Million	80,800 Added 35.91%	305,800 $10.9 Million
Q4 2022 Feb 14, 2023	BUY	$37.12 - $46.52 $935,423 - $1.17 Million	25,200 Added 12.61%	225,000 $8.5 Million
Q3 2022 Nov 14, 2022	BUY	$36.54 - $48.66 $540,792 - $720,168	14,800 Added 8.0%	199,800 $8.84 Million
Q2 2022 Aug 12, 2022	SELL	$31.71 - $43.0 $792,750 - $1.08 Million	-25,000 Reduced 11.9%	185,000 $6.85 Million
Q1 2022 May 16, 2022	SELL	$29.88 - $37.04 $2.84 Million - $3.52 Million	-95,000 Reduced 31.15%	210,000 $7.78 Million
Q4 2021 Feb 14, 2022	BUY	$25.61 - $35.1 $1.02 Million - $1.4 Million	40,000 Added 15.09%	305,000 $9.28 Million
Q3 2021 Nov 15, 2021	BUY	$33.54 - $40.55 $2.68 Million - $3.24 Million	80,000 Added 43.24%	265,000 $8.89 Million
Q2 2021 Aug 16, 2021	BUY	$34.54 - $47.25 $1.89 Million - $2.58 Million	54,600 Added 41.87%	185,000 $7.38 Million
Q1 2021 May 14, 2021	SELL	$42.51 - $63.78 $1.26 Million - $1.89 Million	-29,600 Reduced 18.5%	130,400 $5.86 Million
Q4 2020 Feb 12, 2021	BUY	$45.3 - $60.27 $1.59 Million - $2.11 Million	35,000 Added 28.0%	160,000 $9.05 Million
Q3 2020 Nov 12, 2020	SELL	$47.45 - $62.95 $711,750 - $944,250	-15,000 Reduced 10.71%	125,000 $5.93 Million
Q2 2020 Aug 12, 2020	BUY	$46.85 - $61.05 $4.45 Million - $5.8 Million	95,000 Added 211.11%	140,000 $8.25 Million
Q1 2020 May 14, 2020	BUY	$41.6 - $63.4 $624,000 - $951,000	15,000 Added 50.0%	45,000 $2.13 Million
Q4 2019 Feb 12, 2020	BUY	$53.85 - $65.27 $1.62 Million - $1.96 Million	30,000 New	30,000 $1.81 Million
Q4 2018 Feb 13, 2019	SELL	$43.37 - $59.54 $1.73 Million - $2.38 Million	-40,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$42.88 - $53.7 $3 Million - $3.76 Million	-70,000 Reduced 63.64%	40,000 $2.06 Million
Q2 2018 Aug 13, 2018	BUY	$40.53 - $50.7 $2.03 Million - $2.54 Million	50,000 Added 83.33%	110,000 $4.58 Million
Q1 2018 May 14, 2018	BUY	$44.08 - $55.05 $2.64 Million - $3.3 Million	60,000 New	60,000 $2.65 Million

Others Institutions Holding IONS

# of Institutions

408

Shares Held

148M

Call Options Held

1.72M

Put Options Held

730K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.85B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.

Account

Hudson Bay Capital Management LP Ionis Pharmaceuticals Inc Transaction History